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MAJOR ARTICLE

HIV/AIDS

Efavirenz Pharmacokinetics and
Pharmacodynamics in HIV-Infected Persons
Receiving Rifapentine and Isoniazid for
Tuberculosis Prevention
Anthony T. Podany,1 Yajing Bao,2 Susan Swindells,3 Richard E. Chaisson,4 Janet W. Andersen,2 Thando Mwelase,5
Khuanchai Supparatpinyo,6 Lerato Mohapi,7 Amita Gupta,8 Constance A. Benson,9 Peter Kim,10 and Courtney V. Fletcher1,3;
for the AIDS Clinical Trials Group A5279 Study Team
1

College of Pharmacy, University of Nebraska Medical Center, Omaha; 2Statistical and Data Analysis Center, Harvard School of Public Health, Boston,
Massachusetts; 3Infectious Diseases, Internal Medicine, University of Nebraska Medical Center, Omaha; 4Center for Tuberculosis Research, Johns
Hopkins University School of Medicine, Baltimore, Maryland; 5University of the Witwatersrand, Johannesburg, South Africa; 6Research Institute for Health
Sciences and Faculty of Medicine, Chiang Mai University, Thailand; 7University of the Witwatersrand and Baragwanath Hospital, Soweto, South Africa;
8
Center for Clinical Global Health Education, Johns Hopkins University School of Medicine, Baltimore, Maryland; 9Antiviral Research Center, University of
California, San Diego; and 10Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in
human immunodeﬁciency virus (HIV)–infected individuals receiving a 4-week regimen to prevent tuberculosis.
Methods. Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations
at baseline and weeks 2 and 4 of concomitant therapy. Efavirenz apparent oral clearance was estimated and the geometric mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated. HIV type 1 (HIV-1)
RNA was measured at baseline and week 8.
Results. Eighty-seven participants were evaluable: 54% were female, and the median age was 35 years (interquartile
range [IQR], 29–44 years). Numbers of participants with efavirenz concentrations ≥1 mg/L were 85 (98%) at week 0; 81
(93%) at week 2; 78 (90%) at week 4; and 75 (86%) at weeks 2 and 4. Median efavirenz apparent oral clearance was 9.3
L/hour (IQR, 6.42–13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04–15.59 L/hour) during rifapentine/isoniazid
treatment (GMR, 1.04 [90% conﬁdence interval, .97–1.13]). Seventy-nine of 85 (93%) participants had undetectable
HIV-1 RNA (<40 copies/mL) at entry; 71 of 75 (95%) participants had undetectable HIV-1 RNA at week 8. Two
participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at week 8.
Conclusions. The proportion of participants with midinterval efavirenz concentrations ≥1 mg/L did not cross
below the prespeciﬁed threshold of >80%, and virologic suppression was maintained. Four weeks of daily rifapentine
plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in efavirenz
mid-dosing concentrations or virologic suppression.
Clinical Trials Registration. NCT 01404312.
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Human immunodeﬁciency virus (HIV) and tuberculosis are the leading causes of infection-related deaths
globally [1]. With access to antiretroviral therapy (ART),
HIV may become a manageable chronic disease. However, the presence of coinfection with tuberculosis leads
to an increased level of morbidity and mortality if left
untreated. In 2012, the World Health Organization
(WHO) estimated there were 320 000 deaths in HIV-
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METHODS
Study Population

The AIDS Clinical Trials Group (ACTG) study A5279 is an international, multicenter, randomized, open-label, phase 3 clinical
trial comparing a 4-week daily rifapentine and isoniazid regimen
with a standard 9-month daily isoniazid regimen for the prevention of tuberculosis in HIV-infected participants without evidence of active tuberculosis. An objective of A5279 was to
investigate the effects of concomitant rifapentine and isoniazid
administration on efavirenz pharmacokinetics and to determine
the proportions of participants who had acceptable efavirenz concentrations during concomitant administration of rifapentine and
isoniazid. Overall study inclusion criteria were as follows: HIVinfected men and women at least 13 years of age and 30 kg
body weight, without evidence of active tuberculosis, who either
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have a positive tuberculin skin test or interferon-γ release assay or
live in a high-burden area for tuberculosis (deﬁned as prevalence
of at least 60 cases per 100 000 population). The ﬁrst 90 study participants taking an efavirenz-containing ART regimen for at least
4 weeks prior to study entry and randomized to the rifapentine
plus isoniazid arm of A5279 were enrolled in the pharmacokinetic study. The institutional review boards or ethics committees of
the participating institutions approved the study, and each participant gave written informed consent.
Randomization and Masking

Participants were randomly assigned to either 9 months of daily
isoniazid plus pyridoxine (vitamin B6), or 4 weeks of daily
weight-based rifapentine and isoniazid plus pyridoxine in an
open-label fashion.
Outcomes

The primary outcome of the pharmacokinetic study was the
proportion of participants with efavirenz plasma concentrations
≥1 mg/L while receiving daily rifapentine and isoniazid. The
threshold of ≥1 mg/L was selected because mid-dosing interval
concentrations <1 mg/L have been shown to increase the odds
of virologic failure [14].
A priori rules of adequate proportions of patients with acceptable efavirenz plasma concentrations at both weeks 2 and 4 were
included in the study protocol. Efavirenz pharmacokinetic data
were judged to be acceptable if ≤20% of participants had efavirenz concentrations <1 mg/L at both weeks 2 and 4. Any participant with a baseline (week 0; pre–rifapentine and isoniazid)
efavirenz plasma concentration <1 mg/L was taken as evidence
for efavirenz nonadherence and deemed not evaluable for the
purposes of the pharmacokinetic study.
Putative stopping rules were developed for the pharmacokinetic study should a large proportion of study participants have
unacceptable plasma concentrations of efavirenz while taking
the rifapentine and isoniazid. Pharmacokinetic data were evaluated after enrollment of 9, 21, 31, and 90 participants taking an
efavirenz-containing antiretroviral regimen. At each of these
enrollment milestones, the numbers of participants necessary
to have acceptable efavirenz concentrations at both weeks 2
and 4 according to the stopping rules were ≥4 of 9 participants,
≥12 of 21 participants, and ≥20 of 31 participants, respectively.
These rules were developed to have a high likelihood (≥95%) of
continuing to accrue participants if the true underlying rate of
having acceptable efavirenz concentrations is >80% [15].
The ﬁnal evaluation occurred after 90 participants had been
enrolled in the pharmacokinetic study. In the ﬁnal evaluation,
the exact lower 95% conﬁdence bound was calculated for the
proportion of participants with efavirenz concentrations >1
mg/L during the 4 weeks of LTBI therapy. The efavirenz pharmacokinetic data were deemed acceptable if the lower bound of
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infected individuals related to tuberculosis [1]. HIV-infected individuals with latent tuberculosis (LTBI) are 21–34 times more
likely to develop active tuberculosis than HIV-uninfected individuals [1]. Early detection and treatment of LTBI in HIVinfected individuals is imperative.
Isoniazid has long been the cornerstone of treatment to prevent active tuberculosis. However, current regimens are lengthy
and may be associated with adverse effects. Difﬁculties with adherence to the current isoniazid recommendations lead to high
rates of therapy discontinuation and poor rates of completion
[2]. There is a compelling need to establish shorter and safer
treatment regimens for LTBI in HIV-infected individuals.
Recent data have shown that a 3-month regimen of onceweekly rifapentine plus isoniazid is as effective as the current
standard of care, 9 months of daily isoniazid [3, 4]. However,
the US Centers for Disease Control and Prevention (CDC)
guidelines currently do not recommend use of a rifapentinecontaining regimen in HIV-infected individuals on ART
because possible drug–drug interactions with rifapentine
have not been fully evaluated [5]. Additionally, the International Standards for Tuberculosis Care, developed by TB
CARE, which includes the WHO and the American Thoracic
Society, recommend using isoniazid preventive therapy over
rifapentine-containing regimens for treatment of LTBI in
high-prevalence areas in HIV-infected individuals [6].
Rifapentine is a known cytochrome P450 (CYP) enzyme inducer [7, 8]. Efavirenz-based ART is a ﬁrst-line treatment option
for HIV in both US and international guidelines [9–13]. Efavirenz is a CYP substrate, leading to concern for decreased efavirenz
concentrations and increased risk of virologic failure if dosed
concurrently with rifapentine. The pharmacokinetic characteristics of this combination have not been evaluated. To this end, we
designed a study to evaluate the effect of daily rifapentine plus
isoniazid for 4 weeks on efavirenz pharmacokinetics.

the 95% conﬁdence interval (CI) of the proportion of participants with acceptable efavirenz concentrations at both weeks
2 and 4 did not fall below the prespeciﬁed 80% level.
Procedures

Rifapentine dosing was based on body weight. Participants weighing 30–34.9 kg received 300 mg once daily, participants weighing
35–44.9 kg received 450 mg once daily, and participants weighing
≥45 kg received 600 mg once daily, administered as 150-mg tablets. Rifapentine was provided by sanoﬁ-aventis (France) and isoniazid from multiple manufacturers. Efavirenz was obtained from
local sources at each study site and was approved by national authorities. Patients were instructed to take all doses orally with food.
The isoniazid dose was 300 mg, administered orally as a single tablet, daily with pyridoxine (vitamin B6) 25 mg; isoniazid was to be
taken together with rifapentine and food.
Plasma samples were collected for pharmacokinetic evaluations at study entry (week 0, prior to initiation of rifapentine
and isoniazid) and again at week 2 and week 4 (during rifapentine and isoniazid administration). A mid-dosing interval (12
hours postdose) plasma sample was collected for pharmacologic
evaluation of efavirenz concentrations. Additional plasma samples were collected at baseline and at week 8 ( post–study drug
administration) for HIV type 1 (HIV-1) RNA quantitation. Efavirenz concentrations were quantiﬁed by validated ultra performance liquid chromatography assays as previously described [16].
Pharmacokinetic parameter estimation was accomplished
using maximum a posteriori probability–Bayesian estimation implemented in ADAPT II (Biomedical Simulations Resource at the
University of Southern California, Los Angeles) [17]. The primary pharmacokinetic parameter of interest for efavirenz was apparent oral clearance. Population mean and standard deviation
values for efavirenz apparent oral clearance used in the Bayesian
analysis were 8.0 ± 4 L/hour, and were taken from published literature [18]. Week 0 efavirenz concentrations were used to estimate the prerifapentine plus isoniazid apparent oral clearance of
efavirenz. Plasma concentrations from weeks 2 and 4 were taken
together to estimate the apparent oral clearance of efavirenz during concomitant treatment with rifapentine and isoniazid.

efavirenz dose and efavirenz concentration at weeks 0, 2, and
4. The geometric mean ratio (GMR) and 2-sided 90% CI of
the pre- and on-rifapentine and isoniazid apparent oral clearance
values were calculated. Analyses were done using SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
From May 2012 until May 2013, 97 HIV-infected individuals receiving efavirenz-containing ART were enrolled in the pharmacokinetic study from 5 countries: South Africa, Thailand, United
States, Botswana, and Peru. Seven participants had incomplete
(weeks 0, 2, and 4) PK sample collection. One participant was
hospitalized and did not complete the pharmacokinetic evaluations. One participant had study medication (rifapentine and isoniazid) held and thus did not complete the pharmacokinetic
study, and 1 participant was not included due to the clinic
inadvertently not storing a collected pharmacokinetic sample.
Eighty-seven participants had complete data sets (week 0, 2,
and 4) available for pharmacokinetic analyses (Table 1). The median age of the 87 participants was 35 years (interquartile range
[IQR], 29–44 years); 47 (54%) were female; 48 (55%) were black
non-Hispanic; and 37 (43%) and 31 (36%) of the participants
were from South Africa and Thailand, respectively.
Table 1. Baseline Demographic and Clinical Characteristics
Characteristic
Age, y, median (IQR)

35 (29–44)

Female sex
Race/ethnicity

47 (54)

White non-Hispanic

1 (1)

Black non-Hispanic
Hispanic (regardless of race)

48 (55)
6 (7)

Asian/Pacific Islander

32 (37)

Country of enrollment
Botswana

5 (6)

Peru

Statistical Analysis

Descriptive statistics were used to summarize continuous variables, including age, CD4 counts, and efavirenz treatment duration at study entry. Categorical variables, including race/ethnicity,
country, whether HIV-1 RNA level was detectable, and ART at
study entry, were summarized by frequency distribution. Participants with missing data were not included in the calculations.
Participants with randomized treatment temporarily held prior
to week 4 or incomplete pharmacokinetic evaluations were excluded from the analysis. Median and percentiles were used to
describe the collection time of pharmacokinetic samples post–

Total (N = 87)

2 (2)

South Africa
Thailand

37 (43)
31 (36)

United States

12 (14)

HIV-1 RNA, log10 copies/mLa
Mean (SD)

1.6 (0.2)

Min, Max

1.6, 3.0

Undetectable (<40 copies/mL)
Detectable

79 (93)
6 (7)

CD4 count, cells/µL, median (IQR)

508 (372–649)

EFV duration, wk, median (IQR)

109 (61–233)

Data are shown as No. (%) unless otherwise specified.
Abbreviations: EFV, efavirenz; HIV-1, human immunodeficiency virus type 1;
IQR, interquartile range; SD, standard deviation.
a

Entry HIV-1 RNA was available for 85 of 87 evaluable participants.
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Samples for HIV-1 RNA were collected from 85 of 87 participants at baseline (week 0) and from 75 of 87 participants at
week 8 HIV. Seventy-nine of the 85 (93%) participants had undetectable (<40 copies/mL) plasma HIV-1 RNA at study entry.
Seventy-one of 75 (95%) participants with available week 8
HIV-1 RNA had a undetectable level (<40 copies/mL). Of 75
participants with HIV-1 RNA results at week 8, 71 had undetectable HIV-1 RNA at entry. Two of these 71 (2.8%) had detectable HIV-1 RNA (43 and 47 copies/mL) at week 8. The
median duration of efavirenz containing ART before study
entry was 109 weeks (IQR, 61–233 weeks).
Interim safety evaluations were conducted by assessing the
proportion of participants with acceptable efavirenz concentrations when study enrollment reached 9, 21, and 31 evaluable
participants. As all passed their respective thresholds, the
study was allowed to enroll to full accrual.
Two hundred sixty-one pharmacokinetic samples (87 samples
at each week 0, 2, and 4) were collected at a median post–efavirenz
dose sampling time of 14.8 hours (IQR, 13.5–16.8 hours) at week
0, 14.0 hours (IQR, 12.8–15.6 hours) at week 2, and 13.7 hours
(IQR, 12.7–15.5 hours) at week 4 (Figure 1A). Median week 0
(efavirenz only, no rifapentine/isoniazid) efavirenz concentrations were 2.59 mg/L (IQR, 1.85–3.83 mg/L). Median week 2
(efavirenz + rifapentine + isoniazid) efavirenz concentrations
were 2.46 mg/L (IQR, 1.47–3.81 mg/L), and median week 4
(efavirenz + rifapentine + isoniazid) efavirenz concentrations
were 2.54 mg/L (IQR, 1.44–3.83 mg/L). Eighty-ﬁve (98%) participants had week 0 efavirenz plasma concentrations ≥1 mg/L, 81
(93%) participants had week 2 efavirenz plasma concentrations

≥1 mg/L, and 78 (90%) study participants had week 4 plasma
efavirenz concentrations ≥1 mg/L. Seventy-ﬁve (86%) participants had week 2 and week 4 plasma efavirenz concentrations
≥1 mg/L with a lower 95% CI bound of 78.6%. Excluding (as
per protocol) the 2 participants with efavirenz <1 mg/L at
entry, 75 of 85 (88.2%) had efavirenz ≥1 mg/L at both weeks 2
and 4 with a lower 95% CI bound of 80.8% (Figure 1B and
1C). The median apparent oral clearance of efavirenz was 9.3
L/hour (range, 1.0–33.4) for week 0, prior to initiation of rifapentine and isoniazid, and 9.8 L/hour (range, .8–24.9) for combined
weeks 2 and 4, during rifapentine and isoniazid treatment
(Figure 1D). The GMR of efavirenz apparent oral clearance was
1.04 (on rifapentine and isoniazid to off rifapentine and isoniazid; 90% CI, .97–1.13).
DISCUSSION
In this study of coadministration of rifapentine and isoniazid for
4 weeks in HIV-infected persons receiving an efavirenz-containing
antiretroviral regimen, we found that 88% of participants maintained efavirenz concentrations above the minimum target concentration of 1 mg/L. A nonsigniﬁcant increase in the apparent
oral clearance of efavirenz was observed, consistent with the
well-known CYP induction properties of rifapentine [7, 8]. Of
those participants who had HIV-1 RNA <40 copies/mL at baseline and an available week 8 HIV-1 RNA sample, 97% remained
at <40 copies/mL after completion of rifapentine and isoniazid
therapy. One limitation of the study was that week 8 HIV-1
RNA data were not available for 12 of the patients included in

Figure 1. Efavirenz (EFV) sampling times, hours postdose by week (A), EFV concentrations by week (B), EFV concentrations by week (truncated concentration axis) (C), and EFV apparent oral clearance (CL/F) before and after rifapentine (RPT) and isoniazid administration (D).
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the pharmacokinetic study. However, week 8 HIV-1 RNA data
were available on 86% of the patients with complete pharmacokinetic data available. The ﬁndings provide a pharmacokinetic
and pharmacodynamic basis to support 4 weeks of rifapentine
and isoniazid coadministration for prevention of tuberculosis
in HIV-infected persons also taking efavirenz.
The CDC currently recommends once-weekly directly observed treatment with rifapentine and isoniazid for 12 weeks
as an alternative to 9 months of daily isoniazid for the treatment
of LTBI [5]. This recommendation is based on 3 randomized
clinical trials that have shown the shorter-course regimens to
be as effective as 9 months of daily isoniazid therapy [3, 4,
19]. Utilization rates of efavirenz-containing ART are high
in countries of high tuberculosis prevalence. The rifapentineisoniazid regimen, however, is not recommended for use in
HIV-infected persons receiving ART because potential drug–
drug interactions have not been evaluated. Efavirenz is metabolized by CYP2B6 and CYP2A6 [20], and rifapentine, like rifampin,
is a known inducer of CYP-mediated drug metabolism, with the
potential to lower efavirenz concentrations [7, 8]. In contrast, isoniazid has been shown to inhibit CYP2A6, which may counteract
an induction effect of rifapentine in a select genotypic subset of
individuals [21]. The role of isoniazid in this 3-way drug–drug interaction among rifapentine and efavirenz appears to better predict
and explain high efavirenz plasma concentrations, which may
cause patients to experience adverse drug effects from efavirenz,
as opposed to lower efavirenz concentrations, which may lead to
virologic failure [22–26]. With regard to the interaction between
efavirenz and rifampin, the US Department of Health and
Human Services guidelines for treatment of HIV infection suggest
an increased efavirenz dose of 800 mg daily as an option in patients receiving rifampin who weigh >60 kg [10]. Similarly, the
US Food and Drug Administration–approved package insert for
efavirenz recommends the higher dose of 800 mg daily in patients
weighing ≥50 kg receiving rifampin [27]. The basis for these recommendations is pharmacokinetic studies that have shown an
increase in efavirenz apparent oral clearance and a reduction in
efavirenz concentrations by approximately 30%, and an attempt
to minimize the potential for subtherapeutic concentrations by
increasing the dose of efavirenz [28]. A number of clinical trials,
however, have shown sustained virologic efﬁcacy during concomitant standard-dose efavirenz and rifampin therapy [29–32].
Nonetheless, the lack of any pharmacokinetic and pharmacodynamic data when daily rifapentine is given with efavirenz has precluded a recommendation for coadministration in HIV-infected
individuals on ART.
The challenges of concomitant therapy for HIV infection and
LTBI are not trivial. Current treatment options for LTBI in patients receiving ART are limited to ≥6 months of daily isoniazid
preventive therapy. Despite the demonstrated efﬁcacy of isoniazid
preventive therapy, poor rates of uptake and the high proportion

of individuals who fail to complete even 6 months of isoniazid
preventive therapy highlight the need for alternative, more effective short-course approaches for treatment of LTBI [33]. ACTG
A5279 represents an effort to extend the beneﬁts of a novel,
short-course rifapentine-containing regimen for LTBI treatment
to HIV-infected individuals on ART. We chose to study the rifapentine–efavirenz interaction in this intended patient population,
rather than the more common evaluation of drug–drug interactions in healthy volunteers. To accomplish this, we used a convenient and minimally invasive pharmacokinetic sampling strategy.
Published data support a single mid-dosing interval efavirenz
concentration as informative of the pharmacokinetics and pharmacodynamics of efavirenz [14]. Efavirenz is typically dosed
prior to bedtime; therefore, a 12-hour postdose sampling time
also was convenient for the participants and the clinical sites.
Bayesian analysis allowed us to evaluate the sparse individual participant pharmacokinetic data as it accrued, instead of after complete enrollment. This enabled early protocol stopping rules to
limit enrollment had a clinically signiﬁcant decrease in efavirenz
concentrations been detected. The measurement of plasma HIV1 RNA before and after rifapentine provided a pharmacodynamic
endpoint. These characteristics of this clinical pharmacologic
evaluation, designed as a companion to the larger A5279 clinical
trial, illustrate how necessary drug–drug interaction information
can be efﬁciently and safely obtained. Our ﬁnding that a 4-week
regimen of daily rifapentine and isoniazid can be administered to
HIV-infected persons who are receiving an efavirenz-containing
antiretroviral drug regimen, without clinically meaningful reductions in efavirenz concentrations or virologic suppression, is one
important step that advances the ﬁeld of concomitant therapy for
HIV infection and latent tuberculosis.
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